Bone Marrow Toxicity in HCV Genotype 5a-Infected Patient after peg-IFN alpha-2a and Ribavirin Therapy
Bone Marrow Toxicity in HCV Genotype 5a-Infected Patient after peg-IFN alpha-2a and Ribavirin Therapy
复制标题
DOI：
10.1179/joc.2008.20.5.648
复制
发表时间：
2008-10-01
影响因子：
1.8
通讯作者：
Petrosillo, N.
中科院分区：
文献类型：
--
作者：
Drapeau, C. M. J.;Remotti, D.;Petrosillo, N.
丙型肝炎病毒相关慢性肝炎的最佳治疗方法是聚乙二醇干扰素α（peg-IFN α）和病毒唑（RBV）的联合治疗。不幸的是，聚乙二醇-IFN α和RBV都是造成广泛不良事件和潜在严重毒性的原因，特别是血液学改变。事实上，RBV通常通过溶血引起贫血，而PEG-IFN α更常见地诱导白细胞减少和血小板减少，推测是通过骨髓毒性。事实上，关于HCV感染患者接受IFN-α治疗后骨髓组织病理学改变的数据很少。我们报告一例HCV感染的丙型肝炎患者，谁开发的骨髓改变后，一年聚乙二醇干扰素α加RBV治疗，我们描述了相关的组织病理学特征。我们的病例报告提供了新的显着的组织病理学变化发生在HCV感染的骨髓炎患者在聚乙二醇干扰素α-2a加RBV治疗，也提供了额外的信息，潜在的骨髓毒性的过程中，干扰素为基础的治疗。
The optimal therapy for HCV-related chronic hepatitis is the combination of pegylated interferon alpha (peg-IFN alpha) plus ribavirin (RBV). Unfortunately, both peg-IFN alpha and RBV are responsible for a wide range of adverse events and potentially severe toxicities, particularly hematological alterations. Indeed, RBV is generally responsible for anemia through hemolysis, while peg-IFN alpha induces more commonly leukopoenia and thrombocytopenia, presumably through bone marrow toxicity. Actually, data regarding histopathological bone marrow alterations in HCV-infected patients following IFN-alpha therapy is scanty. We report a case of a HCV-infected cirrhotic patient, who developed bone marrow alterations following one-year peg-IFN alpha plus RBV treatment, and we describe the associated histopathological features. Our case report provides new significant insight on the histopathological changes occurring in bone marrow of HCV-infected cirrhotic patients during peg-IFN alpha-2a plus RBV treatment, providing also additional information on potential bone marrow toxicity in the course of IFN-based treatments.